Immatics has delivered evidence that its TCR-engineered cell therapies can move the needle in solid tumors, revealing 50% of heavily pretreated patients responded to its candidate despite taking less than the target dose. The challenge now? To improve the durability of the responses.
Adaptimmune and Immatics have begun to validate the long-discussed, but previously unfulfilled, potential of TCR-Ts in recent years, pointing to a future in which the modality brings the power of cell therapies to solid tumors. Immatics took another step toward that goal this week with the release of data on 16 patients who received a TCR-T against PRAME, a protein expressed in solid cancers.
